{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:02:36Z","timestamp":1784685756391,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02300-0","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:24:09Z","timestamp":1779744249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Hormone receptor-positive\/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"Sonia","family":"Servitja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Rodr\u00edguez-Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Margeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"L\u00f3pez-Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Amenedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Polonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gil-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"10001","key":"2300_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists' Collaborative G","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"issue":"19","key":"2300_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"34","key":"2300_CR3","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2300_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"9","key":"2300_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-Year efficacy outcomes. J Clin Oncol. 2024;42(9):987\u201393.","journal-title":"J Clin Oncol"},{"key":"2300_CR6","doi-asserted-by":"publisher","first-page":"S1207","DOI":"10.1016\/j.annonc.2024.08.2251","volume":"35","author":"PA Fasching","year":"2024","unstructured":"Fasching PA, Stroyakovskiy D, Yardley D, Huang CS, Crown JP, Bardia A, et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+\/HER2\u2212 early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol. 2024;35:S1207.","journal-title":"Ann Oncol"},{"issue":"23","key":"2300_CR7","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","volume":"363","author":"M Martin","year":"2010","unstructured":"Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363(23):2200\u201310.","journal-title":"N Engl J Med"},{"issue":"20","key":"2300_CR8","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.2012.46.9841","volume":"31","author":"M Mart\u00edn","year":"2013","unstructured":"Mart\u00edn M, Ruiz A, Ruiz Borrego M, Barnadas A, Gonz\u00e1lez S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM\/2003-02 study. J Clin Oncol. 2013;31(20):2593\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2300_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Martin","year":"2008","unstructured":"Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100(11):805\u201314.","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"2300_CR10","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO.2015.61.9510","volume":"33","author":"M Mart\u00edn","year":"2015","unstructured":"Mart\u00edn M, Ruiz Sim\u00f3n A, Ruiz Borrego M, Ribelles N, Rodr\u00edguez-Lescure \u00c1, Mu\u00f1oz-Mateu M, et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM\/2003-10 study. J Clin Oncol. 2015;33(32):3788\u201395.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2300_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-019-05296-8","volume":"177","author":"M Ru\u00edz-Borrego","year":"2019","unstructured":"Ru\u00edz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Ca\u00f1ada JM, et al. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+\/HER2-) early breast cancer (EBC): results from the GEICAM\/2006-10 study. Breast Cancer Res Treat. 2019;177(1):115\u201325.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2300_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016;34(9):927\u201335.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2300_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/jnci\/djaf031","volume":"117","author":"L Arecco","year":"2025","unstructured":"Arecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M, et al. Prognostic implications of risk definitions from the monarchE and NATALEE trials. J Natl Cancer Inst. 2025;117(6):1198\u2013208.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2300_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103008","volume":"9","author":"SWM Lammers","year":"2024","unstructured":"Lammers SWM, Meegdes M, Vriens IJH, Voogd AC, de Munck L, van Nijnatten TJA, et al. Treatment and survival of patients diagnosed with high-risk HR+\/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study. ESMO Open. 2024;9(5):103008.","journal-title":"ESMO Open"},{"issue":"4_Supplement","key":"2300_CR15","doi-asserted-by":"publisher","first-page":"GS1-10","DOI":"10.1158\/1557-3265.SABCS25-GS1-10","volume":"32","author":"A Bardia","year":"2026","unstructured":"Bardia A, Schmid P, Mart\u00edn M, Hurvitz S, Jung K, Rimawi M, et al. Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Clin Cancer Res. 2026;32(4_Supplement):GS1-10-GS11-10.","journal-title":"Clin Cancer Res"},{"key":"2300_CR16","unstructured":"CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+\/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence. In.; 2023."},{"key":"2300_CR17","unstructured":"CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+\/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease. In. Edited by Austrian B, Colorectal Cancer Study G; 2023."},{"key":"2300_CR18","unstructured":"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence. In.; 2022."},{"issue":"2","key":"2300_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"2300_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"2300_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-023-07002-1","volume":"201","author":"M Mart\u00edn","year":"2023","unstructured":"Mart\u00edn M, Carrasco E, Rodr\u00edguez-Lescure \u00c1, Andr\u00e9s R, Servitja S, Ant\u00f3n A, et al. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El \u00c1lamo IV registry. Breast Cancer Res Treat. 2023;201(2):151\u20139.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02300-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:34:16Z","timestamp":1784684056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02300-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sonia Servitja has received speaker honoraria by Daiichi-Sankyo, AstraZeneca, Roche Pharma and Novartis and advisory by Seagen, Genomic Health, MSD and Daiichi-Sankyo. Dr. Eva Carrasco has stock and other ownership interests from Lilly, has received travel and accommodations support from Roche and her husband has participated in consulting and advisory board activities with Bristol-Myers Squibb, Novartis, Celgene, Roche Pharma, Janssen, Amgen, Incyte, Abbvie and Pfizer, has received travel and accommodations support from Celgene, Novartis and Bristol-Myers Squibb. His institution has received research funding from Celgene, Janssen, Bristol-Myers Squibb, Novartis, Celgene, Roche\/Genentech, Amgen, Pfizer and Abbvie. GEICAM has received research funding from Roche\/Genentech, Bristol-Myers Squibb, Novartis, Pfizer, Celgene, AstraZeneca, Merck Sharp & Dohme, Pierre Fabre and Takeda. Dr. Alvaro Rodr\u00edguez-Lescure has received speaker honoraria by Pfizer, Novartis, AstraZeneca, Daichii-Sankyo and Seagen and advisory by Pfizer, Novartis, Roche, AstraZeneca, Daiichi-Sankyo, Pierre Fabre and Seagen. Dr. Miguel Mart\u00edn has received consulting fees from AstraZeneca, Amgen, Taiho Oncology, Roche\/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology and Pfizer; speakers\u2019 honoraria from AstraZeneca, Amgen, Roche\/Genentech, Novartis, Daiichi Sankyo, and Pfizer; and contracted research fees from Roche, Novartis, and PUMA. Dr. Angel Guerrero has received institutional grant by Pfizer, advisory by Novartis, Palex, Pfizer, AstraZeneca, Pierre Fabre, travel grant by Roche Pharma, Pfizer and Novartis and speaker honoraria by Novartis, Pfizer, Lilly, Pfizer, AstraZeneca. Dr. Antonio Ant\u00f3n has received speaker honoraria by Astrazeneca-Daiichi-Sankyo, Eli Lilly and Seagen, advisory by AstraZeneca-Daichii-Sankyo, Eli Lilly, Gilead and personal grant by AstraZeneca-Daiichi-Sankyo, Eli Lilly, Gilead, Pfizer and Seagen. Dr. Isabel \u00c1lvarez has received speaker honoraria by Roche Pharma, advisory by AstraZeneca, Pfizer, Novartis, Roche Pharma and Gilead and research funding by AstraZeneca, Pfizer, Novartis and Roche PharmaDr. Josefina Cruz has received speaker honoraria by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Pierre Fabre, Eisai, Lilly, Daiichi Sankyo, Seagen, Gilead and Pfizer and advisory by Astrazeneca, Roche Pharma, Novartis, PharmaMar, Eisai, Lilly, GlaxoSmithKline, Pfizer, Gilead, Seagen and Daiichi Sankyo. Dr. Sara L\u00f3pez-Tarruella has received speaker honoraria by Lilly and consulting or advisory role by AstraZeneca, Novartis, Roche Pharma, Pfizer, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo Europe GmbH, Gilead Sciences, MSD, GlaxoSmithKline, Veracyte. Dr. Margarita Amenedo has received honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events by Astrazeneca, Merk and Pharma Mar and support for attending meetings and\/or travel by Astrazeneca, Merk, Lilly, Incyte and GSK and Dr. Miguel Gil has received honoraria by Pfizer, Astrazeneca-Daiichi-Sankyo and Gilead, consulting or advisory role by Seagen, Astrazeneca-Daiichi-Sankyo and Astrazeneca and travel\/ accomodations by Novartis, Roche and Pfizer. The rest of the authors have no conflicts of interest. GEICAM has received research funding from Novartis, S.A.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol of the original clinical trials and of the BC registry were approved by an institutional review board and the national regulatory agency. Informed consent was obtained from all individual participants included in the clinical trials. In the BC registry it was not necessary to obtain the informed consent because the national regulatory agency classified it as an observational study not post-authorization, not needing consent, as data were extracted from the patient\u2019s history without interviewing them. The current study was approved by an institutional review board.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"134"}}